Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
Definium Therapeutics (DFTX) will present positive topline data from three Phase 3 studies of DT120 ODT for generalized anxiety disorder (GAD) and major depressive disorder (MDD) at the 2026 NEI Fall Congress. The studies, Panorama, Emerge, and Voyage, showed efficacy and safety, with DT120 ODT receiving FDA Breakthrough Therapy designation for GAD and MDD. The presentations will include comprehensive safety data and support continued clinical assessment.
How this was made
The 30-second read
Why it matters
First public disclosure of positive Phase 3 results for DT120 in GAD and MDD, a key milestone toward FDA approval.
Market read
The data could trigger a price rally for DFTX and influence peer valuations in the psychedelic space.
What to watch
Regulatory timeline and reimbursement landscape remain uncertain.
Background
Definium Therapeutics (Nasdaq: DFTX) is a late‑stage psychedelic biotech focusing on psychiatric disorders.
Ticker impact
Definium Therapeutics disclosed positive topline Phase 3 data for its DT120 program in GAD and MDD for the first time.
upward pressure as market absorbs positive Phase 3 data
Phase 3 readouts are material catalysts for biotech stocks; the data were presented for the first time, creating fresh upside potential.
Market effects
May boost sentiment for psychedelic‑based therapeutics and related biotech peers.
US biotech sector could see modest gains.
Limited to biotech investors; no broad market effect.
Counterpoint
If data are not as robust as presented, the rally could be short‑lived.
Key entities
- companyDefinium Therapeutics
Biopharma developing DT120 psychedelic therapy.
